LOADING
Comparing Merck & Company (MRK) and Salesforce Inc (CRM) across the Health Care and Technology sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | MRK | CRM |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $376.4B | $161.7B |
| P/E Ratio | 122.0 | 24.2 |
| Forward P/E | 55.6 | 15.4 |
| PEG Ratio | 10.47 | 0.87 |
| EPS | $1.25 | $8.64 |
| Revenue Growth (YoY) | 5.1% | 13.3% |
| Profit Margin | 4.8% | 18.7% |
| Return on Equity | 7.0% | 16.9% |
| Dividend Yield | 2.23% | 0.82% |
| Beta | 0.21 | 1.15 |
| 52-Week High | $154.49 | $267.75 |
| 52-Week Low | $75.81 | $146.32 |
| Volume | -- | -- |
Merck & Company is the larger company by market capitalization. Salesforce Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Salesforce Inc has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.